财务亏损情况 - 2024年第三季度净亏损约790万美元，每股0.11美元，2023年第三季度净亏损730万美元，每股0.18美元[8] - 2024年9月净亏损为7887853美元2023年为7338733美元[19] - 2024年9月基本和稀释后每股净亏损为0.11美元2023年为0.18美元[19] 研发费用 - 2024年第三季度研发费用约350万美元，与2023年第三季度的360万美元基本持平[8] - 2024年9月研发费用为3471939美元2023年为3578113美元[19] 销售、一般和管理费用 - 2024年第三季度销售、一般和管理费用约370万美元，较2023年第三季度的290万美元增长约27.3%[9] 总运营费用 - 2024年第三季度总运营费用约720万美元，较2023年第三季度约650万美元增长约10.6%，其中包含约120万美元非现金费用[10] 现金及现金等价物 - 截至2024年9月30日，公司无限制现金和现金等价物约720万美元[10] 产品相关业务 - 2024年4月至9月30日，向230个新办公室培训并运送Mydcombi[4] 市场规模 - 外部估计美国和中国近视市场每年超过30亿美元[2] - 干眼症全球潜在市场规模达50亿美元[3] 资金筹集 - 筹集净收益总计1070万美元[4] 公司计划 - 公司计划本季度对MicroPine的3期CHAPERONE数据进行中期分析[7] 股权相关 - 截至2024年9月30日和2023年12月31日已发行和流通股数未提及具体数字[18] - 2024年9月额外实收资本为179065877 2023年为154486098[18] - 2024年9月累计赤字为175355212 2023年为145491559[18] - 2024年9月股东权益总额为3719303 2023年为8999094[18] - 2024年9月负债和股东权益总额为22796091 2023年为28779374[18] 营收与成本 - 2024年9月营收为1625美元2023年为1198美元[19] - 2024年9月成本为132522美元2023年为13416美元[19]

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET t ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05% (APP13007) that led to its approval by the U.S. Food and Drug Administration as a treatment for inflammation and pain following ocular surgery. ...

Shares of Eyenovia, Inc. (EYEN) have been struggling lately and have lost 7.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ea ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its FDA-approved mydriasis product, Mydcombi, a key step in the approval process for its state-of-the-art Gen-2 Optejet dispensing platform. Mydcombi will undergo 12-month stability testing and other functional testing in the Gen-2 Optejet device that is consistent with feedback from the Type-C meeting on Eyenovia ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase ...

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% ("Clobetasol"), approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery. "The commercial launch of Clobetasol represents a significant milestone for our company, and as the first new ophthalmic steroid to be approved in more than 15 years, a ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercialstage ophthalmic company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced that its strategic partner, Taiwan-based Formosa Pharmaceuticals (TWO:6838), was granted a Taiwan Export License for clobetasol propionate ophthalmic suspension 0.05% ("clobetasol propionate") to allow for shipment of commercial product to the U.S. Clobetasol is ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercialstage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as ...

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The gross proceeds to Eyenovia from this Offering are approximately $5.14 million, before deducting the placement agent's fees and other offering expenses payable by Eyenovia. Eyenovia intends to use the net proceeds from this Offer ...